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Abstract Vesicoureteral reflux (VUR) is the most common
disease of the urinary tract in children. In order to identify
gene(s) involved in this complex disorder, we performed a
genome-wide search in a selected sample of 31 patients with
primary VUR from eight families originating from southern
Italy. Sixteen additional families with 41 patients were
included in a second stage. Nonparametric, affected-only
linkage analysis identified four genomic areas on chromo-
somes 1, 3, and 4 (p<0.05); the best result corresponded to
the D3S3681-D3S1569 interval on chromosome 3 (non-
parametric linkage score, NPL=2.75, p=0.008). This
region was then saturated with 26 additional markers,
tested in the complete group of 72 patients from 24 families
(NPL=2.01, p=0.01). We identified a genomic area on
3q22.2–23, where 26 patients from six multiplex families
shared overlapping haplotypes. However, we did not find
evidence for a common ancestral haplotype. The region on
chromosome 1 was delimited to 1p36.2–34.3 (D1S228-
D1S255, max. NPL=1.70, p=0.03), after additional fine
typing. Furthermore, on chromosome 22q11.22–12.3,
patients from a single family showed excess allele sharing
(NPL=3.35, p=0.015). Only the chromosome 3q region
has been previously reported in the single genome-wide
screening available for primary VUR. Our results suggest
the presence of several novel loci for primary VUR, giving





Vesicoureteral reflux (VUR) (OMIM 193000) is the most
common disease of the urinary tract in children and
affects 1–2% of the Caucasian population [1]. VUR may
be associated with both acquired postinfectious and
congenital parenchymal damage, currently known as
reflux nephropathy (RN) [2, 3]. The most serious
consequence of RN is chronic renal insufficiency (CRI),
leading to end-stage renal failure (ESRF), dialysis, and/or
renal transplantation: 25.4% of children affected with CRI
have RN [4]. As a consequence, the impact of VUR on
public health is considerable and, despite medical and
surgical interventions for the past decades, the incidence
of VUR-related renal failure has not decreased [5].
The reflux may occur isolated or in association with
other congenital abnormalities of kidney/urinary tract
(CAKUT) or as part of syndromic entities, such as renal-
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Naples, Italycoloboma or branchio-oto-renal syndromes [6–8]. The
exact etiology of primary VUR is not known, but it is
probably related to an abnormal morphogenesis of the
ureteral bud, leading to a defect of the ureterovesical
junction [9]. The initial evidence suggesting a genetic
origin of primary VUR came from twin studies, showing an
80–100% concordance for VUR in monozygotic twins vs. a
35–50% concordance in dizygotic twins [10, 11]. Subse-
quent evidence included familial clustering of VUR [12],
ethnic differences between affected and nonaffected
individuals [13], and an increased risk (30–50%) of
developing VUR in first-degree relatives of an index case
[14–16]. From family studies, a range of inheritance
patterns was reported, including autosomal dominant with
incomplete penetrance [17–20], autosomal recessive [21],
polygenic [22], and even X-linked [23].
Previous studies suggest a urinary tract malformation
locus on chromosome 6p [24, 25]. Studies of humans with
chromosomal abnormalities also suggest candidate loci or
genes on chromosomes 10q26 [26], 19q13 (USF2 gene)
[27], and 13q33–34 [28]. Because mutations in PAX2 on
10q24 cause renal-coloboma syndrome, a rare autosomal
dominant disease with kidney anomalies that include VUR,
this gene was also proposed as a candidate [6, 7]. However,
none of these loci or genes has been shown causally related
to primary VUR [19, 20]. Recently, Lu et al. [29] showed
that mutations in the ROBO2 gene contribute to the
pathogenesis of VUR/CAKUT in a small proportion of
families. In the only genome-wide linkage study reported to
date, Feather et al. [18] demonstrated linkage to chromo-
some 1p13 for primary VUR under a model of autosomal
dominant inheritance with reduced penetrance.
Here, we describe the results of the second genome-wide
scan for primary VUR. Differently from previous studies
and aiming to collect a homogeneous sample set, our
patients were ascertained in a single geographic region. Our
results suggest the presence of several novel loci for
primary VUR, giving further evidence for the genetic
heterogeneity of this disorder.
Methods
Patients and families
Fifty-one pedigrees with multiple patients with VUR coming
from Campania (southern Italy) were enrolled in the study
(Fig. 1). All families were ascertained through an index case,
with VUR documented by voiding cystourethrography
(VCUG) in males and direct radionuclide cystography
(RNC) in females and family members. Three pediatric
nephrologists and one radiologist assessed the patients. RN
was diagnosed by DMSA scintigraphy (dimercaptosuccinic
acid labeled with Technetium-99 m) and defined as focal
defects of radionuclide uptake and/or by one-kidney
differential uptake below 43% [30]. VUR grading was
made according to the International Grading System of
Vesicoureteral Reflux [31].
Additional family members were considered as “affected”
based on the presence of reflux documented by VCUG/RNC
and/or the diagnosis of RN, or the detection of ESRF/renal
replacement in absence of other known causes. As VUR may
spontaneously disappear during childhood and adolescence
[32], the finding of scintigraphic signs of RN in relatives of
VUR patients strongly suggests the previous occurrence of
reflux [33]. Individuals with renal symptoms indicative
of VUR, such as previous urinary tract infections and/or
hypertension and/or proteinuria, not supported by additional
findings were classified as “diagnosis unknown”.P a t i e n t s
with secondary VUR, i.e., neurogenic bladder and posterior
urethral valves, or other urinary tract abnormalities, i.e.,
ureterocele and obstructive hydronephrosis, were excluded.
The study focused on primary familial VUR. Eight families
with 31 patients with VUR were selected for study phase 1
(genome scan) according to the following criteria: diagnosis
of primary VUR in absence of any other malformation, two
or more affected individuals per family, and a pattern of
inheritance compatible with an autosomal dominant model.
The second sample (follow-up) consisted of five affected
relative pairs (parent–child trios, ten patients) and 11 small
families (31 patients) fulfilling the same criteria (Fig. 1).
Informed consent from patients and family members
(parents for their children) and approval from the Ethic
Committee at Second University of Naples were obtained
previously.
Laboratory analysis
Genomic DNA was isolatedf r o mp e r i p h e r a lb l o o d
leukocytes by standard techniques and was sent from
the Paediatrics Department of Second University of
Naples to the Department of Clinical Genetics, Erasmus
Medical Centre in Rotterdam. A systematic genome
scan was performed using the ABI Prism MD-10 set
(Applied Biosystems) consisting of 382 short-tandem-
repeat polymorphisms markers (STRPs), average spaced
10 cM. Additional markers for further characterization
of candidate regions were selected from the gender-
average Marshfield genetic map. Information about
marker order and distances were obtained from the
National Center for Biotechnology Information (NCBI)
physical map and Marshfield integrated genetic map.
Polymerase chain reaction (PCR) products were resolved on
an ABI3100 automated sequencer, and genotypes were
analyzed using the GeneMapper software v.2.0 (Applied
Biosystems).
588 Pediatr Nephrol (2008) 23:587–595Linkage analysis
One thousand simulations were performed (SLINK,
MSIM) [34] to investigate the statistical power of our
sample set. An autosomal dominant mode of inheritance
was assumed with a penetrance of 70%, a mutant allele
frequency of 1%, and a phenocopy rate of 1%. The cal-
culations were done under the assumption of genetic
heterogeneity. Assuming 35% of unlinked families, a
maximum total log of odds (LOD) score of 5.4 was
obtained with a low average LOD of 1.58 [standard
deviation (SD)=1.26], after analyzing all eight pedigrees
selected previously. Increasing the percentage of unlinked
families to 50%, a maximum LOD score of 4.94 was
observed (average 0.99, SD=1.04). Families 1, 4, and 12
had the largest contribution to the total LOD score (LOD=
0.86, 1.04, and 1.62, respectively), followed by families 5,
7, and 13 (LOD=0.57). Due to their small size, families 2
and 11 had less contribution to the final LOD (LOD=0.29).
Simulations were calculated in the replication group (11
families) after exclusion of five parent–child trios, giving a
maximum LOD of 4.57 (average 1.49, SD=1.07) and a
maximum LOD of 4.85 (average 1.14, SD=1.08), under
assumption of 35% and 50% unlinked families, respective-
ly. Family 25 with seven patients was the main contributor
to the total LOD score (LOD=1.47). Finally, simulations
were performed in all 19 families (genome scan group and
replication group) reaching a maximum LOD of 9.19
(average of 2.76, SD=1.78) and a maximum LOD of 7.36
(average of 1.71, SD=1.34), under assumption of 35% and
50% unlinked families, respectively.
Mega2 [35] was used to process the genetic data,
whereas the accuracy of allele segregation within the
families was confirmed with Pedcheck. The program
GENEHUNTER v.2.1 [36] was used to compute multipoint
parametric and nonparametric (or model-free) linkage
analysis. As VUR may often disappear with age, all
individuals in whom VUR, RN, or both were not clinically
proven were classified (and analyzed) as “diagnosis
unknown”.T h u s ,ac o n s e r v a t i v e“affected-only” analysis
was performed based on these criteria. Due to the uncertain
pattern of inheritance, nonparametric analysis was computed.
Fig. 1 Selection and distribution of families and patients included in the study. VUR vesicoureteral reflux
Pediatr Nephrol (2008) 23:587–595 589The rationale of a nonparametric analysis is that, among
affected relatives, excess sharing of haplotypes identical by
descent would be expected, irrespective of the mode of
inheritance. The nonparametric linkage statistics examining
all individuals simultaneously (NPL-all), is reported.
A parametric analysis was performed as well. An
autosomal dominant mode of inheritance with reduced
penetrance, as described above (power calculations), was
used. Marker allele frequencies were calculated using all
spouses (unrelated individuals) coming from the same
geographic area. Due to the genetic heterogeneity of the
disease, the genome scan data was analyzed, maximizing
the heterogeneity LOD score (HLOD) with respect to the
proportion of linked families (α). Nonparametric (NPL) and
parametric (LOD) scores were calculated for each of the




Fifty-one pedigrees with multiple patients with VUR, origi-
nating from the same region of southern Italy (Campania),
were available for the study. All persons in the study were
ascertained through an index case documented by VCUG/
RNC. A total of 143 patients were detected. According to the
phenotype, three groups of families were identified: primary
VUR; VUR associated with additional abnormalities of
kidney/urinarytractsuchas duplicatedcollectingsystem,renal
agenesis, or hypospadia; and VUR occurring in syndromes,
such as renal-coloboma, branchio-oto-renal syndromes, and
reflux associated with congenital ichthyosis (Fig. 1).
A total of 78 primary VUR patients belonging to 25
pedigreeswereidentified(33basedonapositiveVCUG/RNC,
Fig. 2 A selection of pedigrees enrolled in the study is shown. Squares
indicate males and circles indicate females. Family members with
unknown phenotype are in grey, whereas those unaffected (normal
voiding cystourethrography or direct radionuclide cystography before
age of 5 years and unrelated spouses) are in white.A nasterisk
highlights the individuals genotyped in the study. A number following
the asterisk indicates the patients/obligate carriers reported in Fig. 3.
Individuals with urinary tract infections by history and “obligate
carriers” are considered as unknown in all analyses. a Nine multiplex
pedigrees included in the genome-wide scan are shown. An additional
five parent–child trios are not displayed. Family 6 was excluded from
the linkage analysis due to the bilineal inheritance. b All 11 multiplex
pedigrees included in the fine-typing stage are shown. VUR
vesicoureteral reflux, RN reflux nephropathy, ESRF end-stage renal
failure, UTIs urinary tract infections
590 Pediatr Nephrol (2008) 23:587–59518 based on detection of RN, 21 diagnosed as having both
reflux and RN, and six with ESRF). During the course of the
study, a new patient affected with RN was detected in family 1
and included in the second stage. Twenty-eight patients were
males and 51 were females (ratio M/F=0.57). The median age
at diagnosis was 3.5 years (range 1 month–68 years). Among
the 79 patients, 19 were treated surgically, and four out of six
who developed ESRF underwent renal transplantation.
The most informative pedigrees are shown in Fig. 2a,b.
The pedigrees showed patients in several generations, and
male-to-male transmission was observed in some families,
supporting an autosomal dominant mode of inheritance. As
reported before for primary VUR, we observed several
obligate carriers in our families, i.e., families 4, 6, 12, and
13. Family 6 is especially interesting: when assessing the
parents (asymptomatic) of the four symptomatic children,
both individuals were found to have RN. No consanguinity
was reported, but history of ESRF in both branches was
described. We are currently recruiting clinical information
of those patients (family 6, second generation, Fig. 2). Due
to this bilinear transmission, this family was excluded from
the linkage analysis.
Genome search
We performed a systematic genome-wide scan using 382
microsatellite markers. Results from both parametric and
nonparametric linkage analysis excluded most of the genome
(data not shown). Furthermore, negative scores were found on
both VUR loci, 1p13 [18]( N P L = −0.86, p=0.86) and 13q33–
34 [28]( N P L = −0.21, p=0.58) previously reported.
We used a nominal p value of < 0.05 to decide whether a
region was promising for further study. Table 1 summarizes
the genome-wide scan results, showing all regions that
yielded a total NPL corresponding to p<0.05. These
regions were located on chromosome 1 (D1S468-D1S255,
D1S213-D1S2785), chromosome 3 (D3S3681-D3S1569),
and chromosome 4 (D4S402-D4S1597). Furthermore, on
chromosome 22q11.22–12.3, patients from a single family
showed excess allele sharing (D22S539-D22S280). The
best evidence of linkage was observed on chromosome
3p12.3–3q24, which yielded the highest NPL score (2.75,
p=0.008, HLOD=1.52, α=0.76) and on chromosome
1p36.32–1p34.3 (NPL=2.22, p=0.02, HLOD=1.13, α=
0.62). Recently, mutations in ROBO2 were described in two
Fig. 2 (continued)
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functional candidate gene for VUR/CAKUT, maps on
chromosome 3p12.3 at the border of our region. Thus, we
retrospectively sequenced all gene exons in our index
patients, and no mutations were found.
The NPL score of 2.15 (p=0.02) on chromosome 4q26–
3 2 . 3w a sm a i n l yd u et of a m i l y4( N P L = 3 . 0 5 ,p=0.062,
LOD=1.3). Yet, allele sharing among the patients of this
family was observed also on chromosome 2p23.2–2p15
(D2S165-D2S337,N P L = 3 . 0 5 ,p=0.062, LOD=1.3). The
only region in which patients from family 12 (Fig. 2)s h o w e d
excess allele sharing was on chromosome 22q11.22–12.3
(NPL=3.65, p=0.015, LOD=1.49). We then closely
inspected the haplotypes from the positive regions in all
genotyped families. Families 1, 2, 5, 7, 11, and 13 displayed
haplotype sharing among each family’s patients on chromo-
some 3p12.3–3q24, supporting the linkage to this area. Thus,
in six out of eight informative families, we observed allele/
haplotype sharing in an overlapping area on chromosome 3q.
We noted also on chromosome 1p haplotype sharing in four
out of eight multiplex families (families 2, 5, 7, and 11)
extending from D1S2667 until D1S255. Therefore, we
decided to explore these genomic areas.
Refinement of the chromosome 3 locus
The chromosome 3q region between D3S3681 and
D3S1569 was saturated with 26 additional microsatellites
markers (average spaced approximately 2 cM). A maxi-
mum HLOD=2.69 (α=0.95) was reached with an NPL=
2.96, p=0.001. In a second stage, the fine mapping was
extended with 16 additional families with 41 patients. The
expansion of pedigrees introduced additional unlinked
families, which lowered the maximum HLOD to 1.24 (α=
Table 1 Summary of the genome-wide scan results. Total nonparametric linkage (NPL) scores with p values <0.05
Pedigrees D1S468-D1S255 D1S213-D1S2785 D3S3681-D3S1569 D4S402-D4S1597
1p36.32–1p34.3 1q41–1q43 3p12.3–3q24 4q26–4q32.3
4–65 cM 242–266 cM 109–158 cM 117–169 cM
1 −0.80 (−1.09) 0.59 (0.19) 2.48 (0.87) −0.37 (0.07)
2 1.34 (0.27) −0.42 (−0.76) 1.34 (0.28) 0.44 (0.27)
4 1.14 (0.72) 0.26 (−0.36) 1.04 (−0.31) 3.05 (1.3)
5 1.9 (0.55) 1.78 (0.55) 1.89 (0.58) 1.69 (0.57)
7 1.59 (0.54) 1.07 (0.42) 1.75 (0.58) −0.33 (−1.37)
11 1.34 (0.27) 1.34 (0.27) 1.34 (0.28) 0.44 (0.28)
12 1.47 (0.19) 1.58 (0.35) 0.65 (0.10) −0.04 (−1.66)
13 1.25 (0.54) 1.97 (0.54) 1.25 (0.57) 1.25 (0.57)
Total NPL (p) 2.22 (p=0.02) 2.35 (p=0.02) 2.75 (p=0.008) 2.15 (p=0.02)
Total HLOD (α) 1.13 (0.62) 0.61 (0.57) 1.52 (0.76) 1.31 (0.51)
NPL and (LOD) scores per family are shown at each locus. Total NPL (p value) and HLOD (α) obtained from the analysis of all eight pedigrees
are displayed. HLOD was obtained maximizing the “heterogeneity” LOD score with respect to the proportion of linked families (α). Negative
NPL and LOD scores indicate no linkage or inconclusive result
NPL nonparametric LOD score, HLOD heterogeneity LOD score, α proportion of “linked” families
Table 2 Summary of fine-typing results in chromosome 1 and 3 (total
NPL scores with p values <0.05)
Pedigrees D1S468-D1S255 D3S3681-D3S1569
1p36.32–1p34.3 3p12.3–3q24
4–65 cM 109–158 cM
1 −0.79 (−2.19) 1.43 (0.74)
2 1.34 (0.28) 1.34 (0.28)
4 1.59 (1.17) 0.46 (−0.43)
5 1.89 (0.56) 1.79 (0.58)
7 1.6 (0.57) 1.75 (0.57)
11 1.34 (0.28) 1.34 (0.28)
12 1.51 (0.05) 0.81(−0.73)
13 1.26 (0.57) 1.98 (0.57)
14 1.41 (0.27) 0.004 (0.001)
15 −0.24 (−0.07) 1.41 (0.28)
16 −0.07 (−0.02) 0.0004 (−0.008)
17 1.41 (0.28) 1.41 (0.28)
18 −0.37 (−0.32) −0.57 (−0.48)
19 0.9 (0.28) −0.81 (−0.9)
20 −0.37 (−0.29) 1.73 (0.48)
21 −0.48 (−0.45) −0.58(−0.48)
22 1.37 (0.27) −0.57 (−0.48)
23 2.43 (0.86) −1.41 (−0.96)
25 0.22 (0.28) 4.63 (1.45)
Total NPL (p) 1.70 (p=0.03) 2.01 (p=0.01)
Total HLOD (α) 1.65 (0.55) 1.24 (0.36)
NPL and (LOD) scores per family are shown at each locus. Total NPL
(p value) and HLOD (α) obtained from the analysis of all eight
pedigrees are displayed. HLOD was obtained maximizing the
“heterogeneity” LOD score with respect to the proportion of linked
families (α). Negative NPL and LOD scores indicate no linkage or
inconclusive result
NPL nonparametric LOD score, HLOD heterogeneity LOD score, α
proportion of “linked” families
592 Pediatr Nephrol (2008) 23:587–5950.36), giving a total NPL=2.01(p=0.01) (Table 2). Pedigree
25 was the main contributor to the total score, with an
NPL=4.63, p=0.03, (LOD=1.45). We then performed a
detailed haplotype analysis in all 24 families. Patients from
families 2, 5, 7, 13, 20, and 25 shared a common region
delimited by markers D3S3641 and D3S1764, containing
36 genes according with the NCBI map, built 36.2. Instead,
families 1 and 11 were sharing a more centromeric area not
overlapping with the other families (Fig. 3). We did not
observe a common “ancestral” haplotype shared across the
families.
Refinement of chromosome 1 locus
The 1p36.22-p34.3 region between D1S468 (4.2 cM) and
D1S255 (65.5 cM) was saturated with seven extra micro-
satellite markers (total 12, spaced 4–5 cM) in the complete
group of 24 families (Table 2). We observed a maximum
HLOD of 1.65 (α=0.55) and NPL of 1.7 (p=0.03). The
haplotype analysis showed allele sharing in families 2, 5, 7,
11, 19, and 23 between D1S228 (29.8 cM) and D1S255
(65.5 cM). Patients from families 13, 14, and 22 displayed
haplotype sharing, but it was limited to the upper or lower
part of the region, thus showing no overlapping with the
rest of the families.
Candidate genes
There were several interesting genes map on the chromosome
3q region. The PPP2R3A gene encodes the protein phospha-
tase 2A, one of four major protein phosphatases identified in
eukaryotic cells, implicated in the regulation of most major
Fig. 3 Haplotype analysis in
families supporting the chromo-
some 3 region after fine typing.
A selection of microsatellite
markers is shown. The shared
genomic region is shown in
grey; recombinants are shown in
white blocks
Pediatr Nephrol (2008) 23:587–595 593metabolic pathways. It has been shown to be expressed
ubiquitously in 15-day-old kidneys, regulating the mitogenic
activity in the early embryonic kidney [37]. The FNDC6 gene
encodes a type of fibronectin, expressed mainly in fetal
kidney [38], implicated in the development of renal basement
membrane [39]. RBP1 and RBP2 genes (Retinol-binding-
proteins type 1 and 2) are involved in the metabolism of
vitamin A, which in its active form of retinoic acid plays a
critical role during kidney development, even connecting
ureters to bladder [40]. The AGTR1 gene encodes the
angiotensin receptor II type 1 (AT1), shown to be related to
gross abnormalities in renal morphogenesis in mutant mice
(hydronephrosis) as well as a poor proliferation of ureteral
smooth cells [41].
Discussion
This study reports the second genome-wide search for primary
VUR.Ourresultssuggesttheexistenceofseverallocimapping
to chromosomes 1, 3, 4, and 22, further supporting the
hypothesis that primary VUR is genetically heterogeneous.
We, as others, encountered several pitfalls when studying
VUR. We observed clinical variability among and within
families and the presence of obligate carriers (individuals
who carry and transmit the disease allele but do not manifest
any disease sign or symptom). Although the appropriate
clinical investigations were performed in several apparently
healthy individuals (carriers), no evidence of disease was
found, indicating a reduced or age-dependent penetrance. As
most of these individuals were recruited during their
adulthood, we could not exclude an earlier disease condition
that evolved to a spontaneous resolution. To overcome these
problems, we first performed a careful clinical evaluation of
patients and available relatives. All individuals older than
5 years of age with insufficient or no evidence of VUR were
classified as diagnosis unknown, despite the consequent loss
of power for the statistical analysis.
We performed the first genome search in VUR that
includes families with the same ethnic origin. In order to
strengthen the genetic homogeneity of the patients, all
families included in this study originated from the same
geographic area in the southern part of Italy. Yet, our results
strongly support that primary VUR is a (highly) genetic
heterogeneous condition. Whereas a large number of our
patients and families supported the chromosome 3q locus,
one relatively large pedigree (family 12) showed evidence of
linkage on chromosome 22. Six of our families supported a
locus on chromosome 3q22.2–23 (149.8–153.2 cM). This
region is fully overlapping with one of the loci reported by
Feather et al. [18]. In their study, the interval on chromosome
3q (from GATA128C02 to D3S1763,1 1 2 –176 cM) showed a
high α (0.98) with an NPL=3, p=0.008. This region was
supported by one of their largest pedigrees (with seven
patients) that was clearly not linked to the chromosome 1p13
locus. It is interesting that two independent studies have
found the same genomic region in distinct groups of patients.
Besides the number of patients included in our genome
scan, the results of the statistical analysis are quite modest
and do not reach the criteria suggested by Lander and
Kruglyak [42] to declare significant linkage. Therefore,
some of the identified loci may represent false positive hits
and should be interpreted with caution.
The complex disease etiology of primary VUR has shown
to be difficult to disentangle. Genetic heterogeneity and lack of
knowledge of the true genetic model for VUR are probably the
main difficulties in the identification of the genetic etiology of
VUR. Although genetic studies in VUR are still in an early
phase, we can presume that primary VUR is likely a complex
disorder, with a number of not fully penetrant genes causing
most of the familiar cases. Finally, primary VUR could be
caused by simultaneous gene-environment interactions.
In conclusion, our results show further evidence for the
genetic heterogeneity in primary VUR. We will next focus
on the refinement of the identified genomic regions and the
sequence analysis of the candidate genes according to their
tissutal expression and biological function. Replication of
the results in additional families will be essential, first to
confirm and eventually to evaluate the contribution of these
loci to the pathogenesis of primary, nonsyndromic VUR.
Acknowledgments This work was in part supported by the
Nierstichting Nederland (grant number C05.2146) and Fondo per gli
Investimenti della Ricerca di Base (FIRB). We gratefully acknowledge
patients and family members for donating samples and undergoing
several tests for the study. We thank D. Di Pinto and C. Migliaccio for
their technical assistance in collecting and preparing DNA samples
and F. Sica for assessing and providing clinical data (family 6). We
thank T. de Vries Lentsch and P. Marati for the artwork. We also
acknowledge Dr. V. Bonifati for his helpful comments and Dr. J.
Nauta and Dr. K. Wolffenbuttel for useful discussions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Scott JE, Swallow V, Coulthard MG, Lambert HJ, Lee RE (1997)
Screening of newborn babies for familial ureteric reflux. Lancet
350:396–400
2. Hoberman A, Chao HP, Keller DM, Hickey R, Davis HW, Ellis D
(1993) Prevalence of urinary tract infection in febrile infants. J
Pediatr 123:17–23
3. Hodson CJ, Twohill SA (1984) The time factor in the development
of sterile renal scarring following high-pressure vesicoureteral
reflux. Contrib Nephrol 39:358–369
594 Pediatr Nephrol (2008) 23:587–5954. Ardissino G, Dacco V, Testa S, Bonaudo R, Claris-Appiani A,
Taioli E, Marra G, Edefonti A, Sereni F (2003) Epidemiology of
chronic renal failure in children: data from the ItalKid project.
Pediatrics 111:e382–e387
5. Craig JC, Irwing LM, Knight JF, Roy LP (2000) Does treatment of
vesicoureteric reflux in childhood prevent end-stage renal disease
attributable to reflux nephropathy? Pediatrics 105:1236–1241
6. Sanyanusin P, Schimmenti LA, McNoe LA, Ward TA, Pierpont
ME, Sullivan MJ, Dobyns WB, Eccles MR (1995) Mutation of the
PAX2 gene in a family with optic nerve colobomas, renal
anomalies and vesicoureteral reflux. Nat Genet 9:358–364
7. Cheong HI, Cho HY, Kim JH, Yu YS, Ha IS, Choi Y (2007) A
clinico-genetic study of renal coloboma syndrome in children.
Pediatr Nephrol 22:1283–1289
8. Abdelhak S, Kalatzis V, Heilig R, Compain S, Samson D, Vincent
C, Weil D, Cruaud C, Sahly I, Leibovici M, Bitner-Glindzicz M,
Francis M, Lacombe D, Vigneron J, Charachon R, Boven K,
Bedbeder P, Van Regemorter N, Weissenbach J, Petit C (1997) A
human homologue of the drosophila eyes absent gene underlies
branchio-oto-renal (BOR) syndrome and identifies a novel gene
family. Nat Genet 15:157–1649
9. Murer L, Benetti E, Artifoni L (2007) Embriology and genetics of
primary vesico-ureteral reflux. Pediatr Nephrol 22:788–797
10. Kaefer M, Curran M, Treves ST, Bauer S, Hendren WH, Peters
CA, Atala A, Diamond D, Retik A (2000) Sibling vesicoureteral
reflux in multiple gestation births. Pediatrics 105:800–804
11. Mebust WK, Foret JD (1972) Vesicoureteral reflux in identical
twins. J Urol 108:635–636
12. Tobenkin MI (1964) Hereditary vesicoureteral reflux. South Med
J 57:139–147
13. King LR (1972) Vesicoureteral reflux: a radiographic sign
common to multiple diseases. JAMA 220:854
14. Kenda RB, Fettich JJ (1992) Vesicoureteric reflux and renal scars
in asymptomatic siblings of children with reflux. Arch Dis Child
67:506–508
15. Parekh DJ, Pope JC 4th, Adams MC, Brock JW 3rd (2002)
Outcome of sibling vesicoureteral reflux. J Urol 167:283–284
16. Van den Abbeele AD, Treves ST, Lebowitz RL, Bauer S, Davis
RT, Retik A, Colodny A (1987) Vesicoureteral reflux in
asymptomatic siblings of patients with known reflux: radionuclide
cystography. Pediatrics 79:147–153
17. Chapman CJ, Bailey RR, Janus ED, Abbott GD, Lynn KL (1985)
Vesicoureteric reflux: segregation analysis. Am J Med Genet
20:577–584
18. Feather SA, Malcolm S, Woolf AS, Wright V, Blaydon D, Reid
CJ, Flinter FA, Proesmans W, Devriendt K, Carter J, Warwicker P,
Goodship TH, Goodship JA (2000) Primary, nonsyndromic
vesicoureteric reflux and its nephropathy is genetically heteroge-
neous, with a locus on chromosome 1. Am J Hum Genet
66:1420–1425
19. Sanna-Cherchi S, Reese A, Hensle T, Caridi G, Izzi C, Kim YY,
Konka A, Murer L, Scolari F, Ravazzolo R, Ghiggeri GM,
Gharavi AG (2005) Familial vesicoureteral reflux: testing repli-
cation of linkage in seven new multigenerational kindreds. J Am
Soc Nephrol 16:1781–1787
20. van Eerde AM, Koeleman BP, van de Kamp JM, de Jong TP,
Wijmenga C, Giltay JC (2007) Linkage study of 14 candidate
genes and loci in four large Dutch families with vesico-ureteral
reflux. Pediatr Nephrol 22:1129–1133
21. Pasch A, Hoefele J, Grimminger H, Hacker HW, Hildebrandt F
(2004) Multiple urinary tract malformations with likely recessive
inheritance in a large Somalian kindred. Nephrol Dial Transplant
19:3172–3175
22. de Vargas A, Evans K, Ransley P, Rosenberg AR, Rothwell D,
Sherwood T, Williams DI, Barratt TM, Carter CO (1978) A family
study of vesicoureteric reflux. J Med Genet 15:85–96
23. Middleton GW, Howards SS, Gillenwater JY (1975) Sex-linked
familial reflux. J Urol 114:36–39
24. Groenen PM, Vanderlinden G, Devriendt K, Fryns JP, Van de Ven
WJ (1998) Rearrangement of the human CDC5L gene by a t(6;19)
(p21;q13.1) in a patient with multicystic renal dysplasia.
Genomics 49:218–229
25. Izquierdo L, Porteous M, Paramo PG, Connor JM (1992)
Evidence for genetic heterogeneity in hereditary hydronephrosis
caused by pelvi-ureteric junction obstruction, with one locus
assigned to chromosome 6p. Hum Genet 89:557–560
26. Ogata T, Muroya K, Sasagawa I, Kosho T, Wakui K, Sakazume S,
Ito K, Matsuo N, Ohashi H, Nagai T (2000) Genetic evidence for
a novel gene(s) involved in urogenital development on 10q26.
Kidney Int 58:2281–2290
27. Groenen PM, Garcia E, Debeer P, Devriendt K, Fryns JP, Van de
Ven WJ (1996) Structure, sequence, and chromosome 19
localization of human USF2 and its rearrangement in a patient
with multicystic renal dysplasia. Genomics 38:141–148
28. Vats KR, Ishwad C, Singla I, Vats A, Ferrell R, Ellis D, Moritz M,
Surti U, Jayakar P, Frederick DR, Vats AN (2006) A locus for
renal malformations including vesico-ureteric reflux on chromo-
some 13q33–34. J Am Soc Nephrol 17:1158–1167
29. Lu W, van Eerde AM, Fan X, Quintero-Rivera F, Kulkarni S,
Ferguson H, Kim HG, Fan Y, Xi Q, Li QG, Sanlaville D, Andrews
W, Sundaresan V, Bi W, Yan J, Giltay JC, Wijmenga C, de Jong
TP, Feather SA, Woolf AS, Rao Y, Lupski JR, Eccles MR, Quade
BJ, Gusella JF, Morton CC, Maas RL (2007) Disruption of
ROBO2 is associated with urinary tract anomalies and confers risk
of vesicoureteral reflux. Am J Hum Genet 80:616–632
30. Polito C, La Manna A, Rambaldi PF, Nappi B, Mansi L, Di Toro
R (2000) High incidence of a generally small kidney and primary
vesicoureteral reflux. J Urol 164:479–482
31. Duckett JW, Bellinger MF (1982) A plea for standardized grading
of vesicoureteral reflux. Eur Urol 8:74–77
32. Mattoo TK (2007) Medical management of vesicoureteral reflux.
Pediatr Nephrol 22:1113–1120
33. Chertin B, Puri P (2003) Familial vesicoureteral reflux. J Urol
169:1804–1808
34. Ott J (1989) Computer-simulation methods in human linkage
analysis. Proc Natl Acad Sci USA 86:4175–4178
35. Mukhopadhyay N, Almasy L, Schroeder M, Mulvihill WP, Weeks
DE (2005) Mega 2: data handling for facilitating genetic linkage
and association analysis. Bioinformatics 21:2556–2557
36. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996)
Parametric and nonparametric linkage analysis: a unified multi-
point approach. Am J Hum Genet 58:1347–1363
37. Svennilson J, Durbeej M, Celsi G, Laestadius A, da Cruz e Silva
AF, Ekblom P, Aperia A (1995) Evidence for a role of protein
phosphatases 1 and 2A during early nephrogenesis. Kidney Int
48:103–110
38. Laitinen L, Vartio T, Virtanen I (1991) Cellular fibronections are
differentially expressed in human fetal and adult kidney. Lab
Invest 64:492–498
39. Ekblom P (1981) Formation of basement membranes in the
embryonic kidney: an immunohistological study. J Cell Biol
91:1–10
40. Batourina E, Choi C, Paragas N, Bello N, Hensle T, Costantini
FD, Schuchardt A, Bacallao RL, Mendelsohn CL (2002) Distal
ureter morphogenesis depends on epithelial cell remodeling
mediated by vitamin A and Ret. Nat Genet 32:109–115
41. Miyazaki Y, Ichikawa I (2001) Role of the angiotensin receptor in
the development of the mammalian kidney and urinary tract.
Comp Biochem Physiol A Mol Integr Physiol 128:89–97
42. Lander E, Kruglyak L (1995) Genetic dissection of complex traits:
guidelines for interpreting and reporting linkage results. Nat Genet
11:541–547
Pediatr Nephrol (2008) 23:587–595 595